Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (3)

2023

  1. Current heart failure disease management and treatment in accredited units from cardiology and internal medicine in Spain

    Revista Clinica Espanola, Vol. 223, Núm. 7, pp. 405-413

2004

  1. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial

    Critical Care Medicine, Vol. 32, Núm. 2, pp. 332-341

2003

  1. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis

    Thrombosis and Haemostasis, Vol. 90, Núm. 4, pp. 642-653